Skip to main content
. 2022 Dec 30;21(8):2876–2884. doi: 10.1111/ajt.16599

TABLE 2.

Observed incidence of anti-nucleocapsid IgG antibodies and levels according to the study group

Month 3 Liver transplant patients
Immunocompetent patients
p
n = 62 n = 62
Anti-nucleocapsid IgG detected; n (%) 48 (77.4) 62 (100) <.001
Anti-nucleocapsid IgG levels; median (IQR) 4.28 (1.64–5.83) 5.41 (4.15–6.95) .002
Month 6 n = 71 n = 71 p
Anti-nucleocapsid IgG detected; n (%) 45 (63.4) 64 (90.1) <.001
Anti-nucleocapsid IgG levels; median (IQR) 1.94 (0.51–4.26) 4.33 (1.98–6.15) <.001